BridgeBio Pharma Announces NDA Submission For Acoramidis

BridgeBio Pharma, Inc. (BBIO) has submitted an NDA for acoramidis to the FDA for the treatment of Transthyretin Amyloid Cardiomyopathy or ATTR-CM. The application was based on positive results from ATTRibute-CM, the Phase 3 study.

Related Keywords

India , ,Spotify Technology ,Drug Administration ,Oneplu Super Frame Rate ,Picture Quality Engine ,California Based New India Bazar ,Fda ,Bridgebio Pharma ,Acoramidis ,